| Literature DB >> 35027758 |
Jorge Mansilla-Soto1,2, Justin Eyquem3,4,5, Sascha Haubner3,4, Mohamad Hamieh3,4, Judith Feucht3,4,6, Noémie Paillon7, Andrés Ernesto Zucchetti7, Zhuoning Li8, Maria Sjöstrand3,4, Pieter L Lindenbergh3,4, Michelle Saetersmoen3,4,9, Anton Dobrin3,4, Mathieu Maurin7, Archana Iyer3,4, Andreina Garcia Angus3,4, Matthew M Miele8, Zeguo Zhao3,4, Theodoros Giavridis3,4,10, Sjoukje J C van der Stegen3,4, Fella Tamzalit4, Isabelle Rivière3,11,12, Morgan Huse4, Ronald C Hendrickson8,12, Claire Hivroz7, Michel Sadelain13,14.
Abstract
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy. Here we edit the TRAC locus in human peripheral blood T cells to engage cell-surface targets through their T cell receptor-CD3 complex reconfigured to utilize the same immunoglobulin heavy and light chains as a matched CAR. We demonstrate that these HLA-independent T cell receptors (HIT receptors) consistently afford high antigen sensitivity and mediate tumor recognition beyond what CD28-based CARs, the most sensitive design to date, can provide. We demonstrate that the functional persistence of HIT T cells can be augmented by constitutive coexpression of CD80 and 4-1BBL. Finally, we validate the increased antigen sensitivity afforded by HIT receptors in xenograft mouse models of B cell leukemia and acute myeloid leukemia, targeting CD19 and CD70, respectively. Overall, HIT receptors are well suited for targeting cell surface antigens of low abundance.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35027758 PMCID: PMC9469647 DOI: 10.1038/s41591-021-01621-1
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 87.241